Rapid rituximab infusion is safe and well tolerated in malignant and benign disease.
| Autor: | Ursu SG; Division of Hematology and Cellular Therapy, 6596Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA., Rinchuse DL; Division of Hematology and Cellular Therapy, 6596Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA., Lister J; Division of Hematology and Cellular Therapy, 6596Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2021 Dec; Vol. 27 (8), pp. 1919-1922. Date of Electronic Publication: 2020 Dec 07. |
| DOI: | 10.1177/1078155220978450 |
| Abstrakt: | Introduction: Although the safety and feasibility of rapid rituximab administration has been demonstrated for B-cell malignancies, there is scant data in the literature to support its use in patients with benign diseases. Objective: To identify the incidence of infusion-related reaction with rapid rituximab administration in malignant and benign disease. Secondary objective was to determine the infusion time saved between standard administration and rapid rituximab administration. Methods: A retrospective cohort study was conducted by reviewing electronic medical records from December 2018 to April 2020. Adult patients who received at least one dose of rapid rituximab were included. Results: A total of 63 patents were included. The incidence of an infusion-related reaction with rapid rituximab was 1.6%. The one patient who reacted had a diagnosis of neuromyelitis optica. The mean infusion time saved was 2.9 hours (95% CI: 2.7-3.1; P-value <0.001). Conclusion: The use of the rapid rituximab administration is safe and well tolerated in both benign and malignant disease. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|